Recital 6, Commission Regulation (EU) No 384/2010 of 5 May 2010 on the authorisation and refusal of…

In forcesince 5 May 2010

Following an application from Danone France, submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Danacol® on blood cholesterol (Question No EFSA-Q-2008-779) [The EFSA Journal (2009) 1177, 1-12.]. The claim proposed by the applicant was worded as follows: ‘Danacol® reduces LDL-cholesterol by 10 % in 3 weeks, and the reduction is maintained with daily consumption. High blood cholesterol is one of the main risk factors in the development of (coronary) heart disease’.